Successful decision for Sanofi before the EUIPO. The Board of Appeal confirmed a likelihood of confusion between EUTM Applications BCOVAXIN (word mark) and COVAXIN BHARAT BIOTECH (figurative mark) and Prior EUTM Registration COVAXIS for vaccines and recognized the genuine use of Sanofi’s prior EUTM Registration based on evidence of use provided for Germany (appeal deadline not yet expired).

Sanofi was represented by Cristina Bercial-Chaumier, Attorney at Law at the Alicante Bar, Agente de la Propiedad Industrial (Spanish Patent & Trademark Attorney) and European Trademark and Design Attorney.